StopDown
Funding · 9 July 2026IswaryaRs 350 croreFertility treatment centers across India

Iswarya raises Rs 350 crore from OrbiMed Asia

By · Editor ·

growthFounded 1986
  • Iswarya operates over 85 fertility centers across eight Indian states
  • The company secured Rs 350 crore in growth investment from OrbiMed Asia
  • Funds will support new centers and digital infrastructure in underserved markets

What happened

  • Iswarya has raised Rs 350 crore in a growth investment round.
  • The funding comes from global healthcare investor OrbiMed Asia.
  • This is the first major funding event detailed in the provided facts.
  • The investment marks a significant capital injection for the fertility chain.
  • OrbiMed Asia leads this specific growth stage financing deal.
  • The company plans to use the funds for strategic expansion.
  • This round supports Iswarya's continued growth across its existing network.
  • The deal highlights investor confidence in the Indian fertility sector.

Why it matters

  • OrbiMed Asia is a global healthcare investment firm with expertise in health tech.
  • The investment signals strong demand for specialized fertility services in India.
  • Growth funding allows Iswarya to scale operations without immediate profitability pressure.
  • The deal underscores the maturation of the private healthcare investment landscape.
  • Expansion into underserved geographies addresses gaps in reproductive healthcare access.

The business

  • Iswarya provides IVF, IUI, and advanced reproductive treatments.
  • Services include fertility preservation and comprehensive genetics testing.
  • The company operates 85+ centers across eight Indian states.
  • It has served over 300,000 couples since its establishment in 1986.
  • Dr. Arun Muthuvel serves as Managing Director and founder.
  • The business model relies on high-volume clinical service delivery.
  • Centers are located in both established and emerging medical hubs.
  • The company focuses on patient experience and clinical outcomes.
  • Digital capabilities are part of their operational infrastructure strategy.

The founders

Dr. Arun Muthuvel

Managing Director
  • Established Iswarya in 1986.
  • Leads the company's overall management and strategic direction.
  • No additional educational or prior professional details are provided in the facts.

Dr. Chandralekha

Management Team Member
  • Part of the core management team mentioned by the investor.
  • Specific background details are not included in the provided facts.

Who put in money

  • OrbiMed Asia lead — Global healthcare investment firm led by Dr. Sunny Sharma and Arun Sadhanandham.

In numbers

Rs 350 crore ($37M)Funds Raised
85+Centers
8States Operated In
>300,000Couples Served
Four decadesYears of Operation

What happens next

  • Opening new centers in existing and underserved markets.
  • Investing in clinical infrastructure and digital capabilities.
  • Building an embryology talent pipeline.
  • Deepening pan-India presence through geographic expansion.

Earlier rounds

  • growth · Rs 350 crore ($37M) · led by OrbiMed Asia

Words to know

IVF
In Vitro Fertilization (a process where an egg is combined with sperm outside the body).
IUI
Intrauterine Insemination (placing sperm directly into the uterus during ovulation).
Growth Investment
Capital provided to an established company to expand operations, rather than starting up.

The numbers around it

Healthcare & Life Sciences in July 2026: 11 rounds with a disclosed amount, $87.1 million in all; the biggest was Iswarya (Rs 350 crore). Every sector this year →

Read it as a card in the app

Everything on Iswarya → · All startup news on 9 July 2026 →

Is this Iswarya? Get your “Featured on StopDown” badge →